Colorectal cancer is a major public health concern in China and is expected to become the second-most-common cancer in the country by 2029. The treatment of metastatic colorectal cancer is dominated by chemotherapy regimens prescribed in combination with VEGF inhibitors and EGFR inhibitors. Unlike in the major markets, only a few targeted therapies—including Roche’s Avastin, Merck’s Erbitux, and Bayer’s Stivarga—are available in China for the treatment of colorectal cancer. However, the recent launch of PD-(L)1 inhibitors—Merck’s Keytruda and Alphamab Oncology’s envafolimab—and the anticipated launch and uptake of more targeted therapies—Amgen’s Vectibix, Bayer’s Zaltrap, and Chia Tai Tianqing Pharmaceutical’s Focus V—during the 2021-2031 period will lead to significant growth of China’s colorectal cancer therapy market. Nonetheless, the need for additional effective, targeted therapies for colorectal cancer will remain high, representing a lucrative opportunity for drug developers. Additionally, following the recent reforms in China’s regulatory and reimbursement landscape, manufacturers—both domestic and multinational—will be increasingly incentivized to enter the market over the coming years.
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Qualitative and quantitative insights driven by five country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other DRG research.
Diagnosed prevalence of colorectal cancer by BRAF and RAS biomarker status and by disease stage. Clinically relevant and market-relevant drug-treatable populations.
Ten-year, annualized, drug-level sales and patient shares of key colorectal cancer therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: > 10 drugs; Phase II: > 10 drugs; coverage of select early-phase products.